Related Experiment Video

Updated: Jun 27, 2026

Isolation of Mesenchymal Stem Cells from Human Alveolar Periosteum and Effects of Vitamin D on Osteogenic Activity of Periosteum-derived Cells
06:47

Isolation of Mesenchymal Stem Cells from Human Alveolar Periosteum and Effects of Vitamin D on Osteogenic Activity of Periosteum-derived Cells

Published on: May 4, 2018

Mitogen activated protein kinase-dependent inhibition of osteocalcin gene expression by transforming growth

Sukyee Kwok1, Nicola C Partridge, Narasaimhan Srinivasan

  • 1Department of Physiology and Biophysics, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA.

Journal of Cellular Biochemistry
|December 4, 2008
PubMed

Insights

Transforming growth factor-beta (TGF-beta1) inhibits osteoblast differentiation by affecting the Runx2 transcription factor. This inhibition involves post-translational modifications of Runx2, specifically phosphorylation via the MAPK pathway.

Area of Science:

  • Bone biology and skeletal development
  • Cell signaling pathways
  • Molecular mechanisms of gene regulation

Background:

  • Transforming growth factor-beta (TGF-beta) is crucial for osteoblast differentiation and bone development.
  • TGF-beta's inhibitory role in osteoblast differentiation gene expression is known, but the precise mechanism remains unclear.
  • Runx2, a key transcription factor for osteoblast differentiation genes, is a primary target of TGF-beta inhibition.

Purpose of the Study:

  • To elucidate the mechanism by which TGF-beta1 inhibits osteoblast differentiation gene expression.
  • To investigate the role of the transcription factor Runx2 in TGF-beta1-mediated inhibition.
  • To identify the signaling pathways involved in TGF-beta1's effect on Runx2 activity.

Main Methods:

  • Transient transfection assays to assess osteocalcin promoter activity.
  • Western blotting and co-immunoprecipitation to analyze Runx2 protein expression, localization, and phosphorylation.
  • Treatment with mitogen-activated protein kinase (MAPK) inhibitors.

Main Results:

  • TGF-beta1 inhibited osteoblast differentiation gene expression without altering Runx2 expression levels.
  • TGF-beta1 suppressed osteocalcin promoter activity, mediated through Runx2.
  • Runx2 protein levels, cellular localization, and DNA binding affinity remained unchanged post-TGF-beta1 treatment.
  • Co-immunoprecipitation revealed increased Runx2 phosphorylation upon TGF-beta1 treatment.
  • MAPK inhibitors reversed the TGF-beta1-induced inhibition of Runx2-mediated osteocalcin expression.

Conclusions:

  • TGF-beta1 inhibits osteoblast differentiation through post-translational modification of Runx2, specifically phosphorylation.
  • The mitogen-activated protein kinase (MAPK) pathway is essential for mediating TGF-beta1's inhibitory effects on Runx2.
  • These findings highlight a novel regulatory mechanism involving Runx2 phosphorylation in TGF-beta1 signaling during osteoblast differentiation.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...